Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-18

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ODM-207 in Patients With Advance Solid Tumours

NCT03035591

Solid Tumors

COMPLETED PHASE1/PHASE2

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

NCT06725758

Solid Tumours

RECRUITING PHASE1/PHASE2

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

NCT07101705

Multiple Myeloma (MM) Non-Hodgkin Lymphoma (NHL)

RECRUITING EARLY_PHASE1

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

NCT01423903

Advanced Cancer

COMPLETED PHASE1

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

NCT00820560

Solid Tumors and Hematologic Malignancy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The safety profile of ODM-203 will be explored together with the pharmacokinetics, pharmacodynamics and tumour response to treatment with ODM-203 to recommend the dosing regimen for further clinical studies. The pharmacokinetic properties of ODM 203 will be evaluated after single and multiple dose administrations at different dose levels

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumours

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ODM 203

Oral capsules given once daily dosage 50-800mg

Group Type EXPERIMENTAL

ODM 203

Intervention Type DRUG

ODM 203

Intervention Type DRUG

ODM 203

ODM-203

Oral tablets given once daily 200-1600mg

Group Type EXPERIMENTAL

ODM 203

Intervention Type DRUG

ODM 203

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ODM 203

Intervention Type DRUG

ODM 203

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Male and female subjects over 18 years of age
* Subjects with histologically or cytologically confirmed locally advanced or metastatic tumours. Subjects in Part 2 to have a tumour/genetic aberration.
* Availability of tumour sample for genetic analysis
* Adequate haemopoietic, hepatic and renal function
* Eastern Cooperative Oncology Group performance status of 0 to 1
* Serum mineral levels phosphate: 2.5 mg/dl; calcium: 8.8 mg/dl; magnesium: 1.2 mg/dl; potassium: 11.7 mg/dl; sodium: 299mg/dl.
* Recovery from reversible adverse events of previous systemic anti-cancer therapies to baseline or grade 1 with the exception of alopecia;stable neuropathy of grade 2 induced by previous cancer treatment
* Life expectancy of 12 weeks or more

Exclusion Criteria

* Any prior anti VEGFR/FGFR treatment related AE that in the judgement of the investigator is considered severe/life threatening
* Subjects receiving warfarin
* Active central nervous system metastases not controlled by prior surgery/radiotherapy and/or low dose steroids for 4 weeks or more
* Subjects with current evidence of endocrine alteration of calcium-phosphate homeostasis
* Concomitant therapies known to increase serum phosphorus and/or calcium levels that cannot be discontinued or switched to a different therapy are not permitted within 14 days before the first dose of ODM-203.
* Significant cardiovascular conditions/circumstances as follows:
* a active or unstable cardio/cerebro-vascular disease
* b Uncontrolled hypertension (systolic blood pressure ≥ 150mmHg and/or diastolic blood pressure ≥ 90mg Hg with optimised antihypertensive therapy.
* c history of severe arrhythmia, familial arrhythmia, conduction abnormality or congenital long QT syndrome
* dConcomitant therapies known to prolong the QT interval and associated with a risk of Torsades de Pointes are not permitted within 7 days before the first dose of ODM 203
* e Repeatable prolongation of QTcF interval ≥ 450 msec or any clinically significant abnormality in the ECG at screening in 2 out of 3 recordings
* f Left ventricular ejection fraction \<50% at screening
* Subjects who received systemic anticancer treatment prior to the first dose of ODM-203 within the following timeframes: less than 28 days since the last dose of antineoplastic therapy and/or 28 days of wide field radiotherapy or 14 days of limited field radiation for palliation
* Major surgery or serious infection within 21 days of the first dose of ODM-203
* Known gastrointestinal disease or a procedure that may affect absorption of ODM 203
* Serious concurrent medical condition or psychiatric illness
* History and/or current evidence of ectopic mineralisation/calcification
* Known active or past history of other primary malignancy
* Female of child bearing potential
* Female of child bearing potential or male subject with a female partner of child bearing potential who does not agree to use effective contraception during the study and for 3 months after the last dose of ODM 203
* Known hypersensitivity to the study treatment excipients
* Any condition which in the opinion of the investigator would impair the subject's ability to comply with the study procedures
* Participation in another interventional clinical trial/ concurrent treatment with any investigational drug within 4 weeks prior to the start of treatment with ODM 203

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No